2. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins С. Prevention of meningococcal disease by group C polysaccharide vaccines. N. Engl. J. Med. 1970; 282: 417–20. DOI: 10.1056/NEJM197002192820803

3. Dull P.M., McIntosh E.D. Meningococcal vaccine development – from glycoconjugates against MenACWY to proteins against MenB – potential for broad protection against meningococcal disease. Vaccine 2012; 30: B18–25. DOI: 10.1016/j.vaccine.2012.01.062

4. Vella M., Pace D. Glycoconjugate vaccines: an update. Expert Opin. Biol. Ther. 2015; 15: 529–46. DOI: 10.1517/14712598.2015.993375

5. Chen W.H., Neuzil K.M., Boyce C.R. ,Pasetti M.F., Reymann M.K., Martellet L. et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect. Dis. 2018; 18: 1088–96. DOI: 10.1016/S1473-3099(18)30400-6

6. Christodoulides M., Heckels J. Novel approaches to Neisseria meningitidis vaccine design. Pathog. Dis. 2018; 75: ftx033. DOI: 10.1093/femspd/ftx033

7. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33: 530–41. DOI: 10.1016/j.immuni.2010.09.017

8. Rappuoli R., Pizza M., Masignani V., Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev. Vaccines 2018; 17: 1111–21. DOI: 10.1080/14760584.2018.1547637

9. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S. et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 2009; 200: 379–89. DOI: 10.1086/600141

10. Perez J., Absalon J., Beeslaar J., Balmer P., Jansen K.U., Jones N.R et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev. Vaccines. 2018; 17: 461–77. DOI: 10.1080/14760584.2018.1483726

11. Hoiseth S.K., Murphy E., Andrew L., Vogel U., Frosch M., Hellenbrand W. et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr. Infect. Dis. J. 2013; 32: 1096–101. DOI: 10.1097/INF.0b013e31829aa63b

12. Rodrigues C.M.C., Lucidarme J., Borrow R., Smith A., Cameron J.C., Moxon E.R. et al. Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010–2016. Emerg. Infect. Dis. 2018; 24: 673–82. DOI: 10.3201/eid2404.171480

13. Jafri R.Z., Ali A., Messonnier N.E., Tevi-Benissan C., Durrheim D., Eskola J. et al. Global epidemiology of invasive meningococcal disease. Popul. Health Metr. 2013; (11): 17.

14. Wang B., Santoreneos R., Giles L., Haji Ali Afzali H., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine 2019; 37: 2768–82. DOI: 10.1016/j.vaccine.2019.04.020

15. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; (10): 853–61. DOI: 10.1016/S1473-3099(10)70251-6

16. Bénarda S., Wright C., Voisine J., Olivier C.W., Gaudelus J. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. Journal of Infection and Public Health 2016; (9): 339–47. DOI: 10.1016/j.jiph.2015.10.016

17. Wright C., Wordsworth R., Glennie L. Counting the Cost of Meningococcal Disease Scenarios of Severe Meningitis and Septicemia. Pediatr. Drugs 2013; 15: 49–58. DOI: 10.1007/s40272-012-0006-0

18. Darbà J., Kaskens L., Hark M., Wright C. Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014; 32: 5006–12. DOI: 10.1016/j.vaccine.2014.07.019

19. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2020. 340 с.

[On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report]. Moscow, 2020. 340 p. (In Russ.).

20. Костюкова Н.Н., Бехало В.А., Чернышова Т.Ф. Менингококковая инфекция в Российской Федерации: прошлое и ближайшие перспективы. Эпидемиология и инфекционные болезни 2014; (2): 73–9

Kostyukova N.N., Bekhalo V.A., Chernyshova T.F. [Meningococcal infection in the Russian Federation: past and immediate prospects]. Epidemiology and infectious diseases 2014; (2): 73–9. (In Russ.).

21. Meningococcal vaccines: WHO position paper, November 2011. Weekly epidemiological record 2011; 47(86); 521–40. https://www.who. int/publications/i/item/WER8647